Prescribing patterns among patients treated with ustekinumab for Crohn disease were presented at the 2019 AIBD Annual Meeting.
All articles by Lea Eslava-Kim, PharmD
Etrolizumab is an investigational humanized monoclonal anti-ß7 antibody with a dual mechanism of action.
Treatment with adalimumab or infliximab in biologic-naive patients with Crohn disease or ulcerative colitis demonstrated similar outcomes on Patient-Reported Outcomes Measurement Information System measures and rates of corticosteroid-free remission.
Biosimilar BI 695501 demonstrated non-inferior efficacy and similar safety profile compared with the reference product adalimumab in patients with active Crohn disease.